Figure 5

Personalized drivers in TCGA ovarian cancer samples. (A) The darker red/blue entries (red for point mutations and blue for CNVs) indicate the personalized drivers that are significant and not documented in CGC. The lighter entries are mutations that are not considered as drivers by DawnRank in specific samples. The X-axis includes patient samples with a personalized driver that is significant and not documented in CGC. On the Y-axis, rare drivers (frequency <2%) are in blue and non-rare drivers (frequency >=2%) are in purple. (B) Part of the gene interaction network where TRAF6 is involved. The size of the node scales according to the DawnRank score in ovarian cancer patient sample TCGA-13-1410 and the color intensity scales with differential expression. Note that this figure shows the impact of TRAF6 to other genes in the network, but not all the edges where TRAF6 is not involved are shown due to space limitation (for example, the large number of outgoing edges of TP53). (C) A close-up view of the protein structure of TRAF6 indicates that an amino acid change from the mutation in ovarian cancer patient sample TCGA-13-1410 causes substitution of the Arginine (R) to Tryptophan (W). The substitution of the mutation occurs in a conserved binding site, and the substitution from a charged Arginine to a non-polar aromatic amino acid Tryptophan may suggest a change in the substrate binding with the CD40 peptide substrate.